John Sampson to lead Duke’s physician practice of over 1,500 members

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

John Sampson was elected president of the Private Diagnostic Clinic, the physician practice of Duke Health, with 1,650 members practicing in Duke hospitals and more than 100 clinics in North Carolina.

Sampson will continue to serve as chair of the Duke Department of Neurosurgery. The PDC is one of the first and the largest academic multi-specialty group practices in the U.S., with 1.7 million patient visits in FY18 and $850 million in total revenue.

In addition to patient care, PDC members conduct research and serve as faculty in the Duke University School of Medicine. The PDC collaborates with other entities within the Duke University Health System to expand opportunities and advance Duke’s clinical, research, and academic missions.

In this role, Sampson will provide strategic direction and oversight of the financial and management aspects of the physician organization. This includes implementing initiatives to best position the PDC for continued growth and success, and leading, on behalf of PDC members, the due diligence and negotiations of the potential integration of the PDC and Duke University Health System.

Sampson is the Robert H. and Gloria Wilkins Distinguished Professor and co-leader of the Duke Cancer Institute Neuro-Oncology program. He is a recognized leader in the surgical resection and experimental treatment of complex brain tumors.

He currently focuses his clinical practice on treating patients with benign and malignant brain tumors and divides his time between his clinical practice and an active research laboratory investigating new modalities of direct brain tumor infusion and immunotherapy.

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login